Read more
6:32 PM · 31 October 2023

Sarepta slumps 40% after disappointing drug trials

Sarepta Therapeutics (SRPT.US) is trading under massive pressure today. Stock is down around 40% on the day, following disappointing results of drug trial. Early evidence suggested that Elevidys drug developed by Sarepta is effective in treatment of patients with Duchenne muscular dystrophy, leading the US Food and Drug Administration to approve its use for a limited number of patients.

However, final trial results that were just published turned out to be disappointing and were not statistically significant to rule the drug effective. As such, Sarepta failed to reach its primary goal, which was broader approval for Elevidys, and missed a chance to boost its sales.

Shares of Sarepta launched today's trading with a big bearish price gap. While part of the drop has been recovered during the cash session, stock is still around 40% lower on the day. A key, multi-year support zone in the $65 per share area is being tested at press time.

Source: xStation5

16 April 2026, 4:12 PM

US Open: S&P 500 at all-time high 📈Charles Schwab decline 4.5% despite strong earnings report

16 April 2026, 12:46 PM

Netflix stock up 18% since the start of 2026 📊 Q1 earnings in focus

16 April 2026, 12:11 PM

U.S. energy and utilities sectors in focus 🔍 What will S&P 500 companies show?

16 April 2026, 9:53 AM

TSMC delivers a record quarter. AI is driving results and reshaping the entire cycle

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits